Wiliams, R.T.

patient antibody thrombocytopenia heparin heparin-induced thrombocytopenia study anti-pf 4/heparin antibodies platelet death syndrome anti-pf group 4/heparin heparin-induced end point event factor model revascularization 30- circulation heparin exposure 30- day mi thrombosis table therapy infarction count point thrombin inhibitors thrombin 30- day warkentin 30- day death sample odds ratio trial inhibitor thrombotic serum value population ischemic gusto /negative result artery abciximab platelet count infarction study group exposure significance thrombotic events assay hypertension unfractionated heparin regression analysis heart thromb haemost gusto iv-acs trial percutaneou ischemic syndromes r ischemic syndromes diabetes heparin therapy predictor coll cardiol 2 groups ratio 48 hours david c anti-pf 4/heparin iv-ac weight 30 days anti-pf 4 antibodies association antibody-negative group mi antibody serum samples